PuSH - Publication Server of Helmholtz Zentrum München

Pohla, H.* ; Frankenberger, B. ; Stadlbauer, B.* ; Oberneder, R.* ; Hofstetter, A.* ; Willimsky, G.* ; Pezzutto, A.* ; Dörken, B.* ; Blankenstein, T.* ; Schendel, D.J.

Allogeneic vaccianation for renal cell carcinoma: development and monitoring.

Bone Marrow Transplant. 25, 2, 83-87 (2000)
DOI
Open Access Green as soon as Postprint is submitted to ZB.
An allogeneic tumor cell vaccine should display a natu- ral immunogenicity that allows the stimulation of tumor-reactive effector cells in patients. Furthermore, the vaccine should express antigens that are shared by many tumors to which patients are not tolerant. A var- iety of tumor peptides should be presented by different HLA-molecules due to limited MHC matching with recipients and last but not least, the vaccine should have a strong growth potential in vitro to allow adequate amounts of vaccine to be generated for long-term usage. In vitro and in situ studies with the renal cell carcinoma cell line RCC-26 demonstrate: (1) RCC-26 can induce complex allospecific responses through direct priming; (2) RCC-26 can not only reactivate cytotoxic T lympho- cytes (CTL) of a memory phenotype but they also can induce de novo tumor-antigen associated responses in normal donors; (3) these cells present epitopes restric- ted by several MHC molecules, allowing the vaccination of patients matched for different HLA alleles; and (4) they stimulate HLA-A*0201-restricted T cells bear- ing characteristic T cell receptors (TCR). Thus, in addition to using limiting dilution killer and ELISPOT assays, molecular tracking of a tumor-specific TCR can be used to judge the development of antitumor reac- tivity and vaccine efficiency.
Altmetric
Additional Metrics?
[➜Log in]
Edit extra informations Login
Publication type Article: Journal article
Document type Scientific Article
Corresponding Author
Keywords renal cell carcinoma allogeneic vaccination immune monitoring chromium release lanthanide release ELISPOT TCR tracking
ISSN (print) / ISBN 0268-3369
e-ISSN 1476-5365
Journal Bone Marrow Transplantation
Quellenangaben Volume: 25, Issue: , Pages: 83-87, Article Number: , Supplement: 2
Publisher Nature Publishing Group
Non-patent literature Publications
Reviewing status Peer reviewed
Institute(s) Institute of Molecular Immunology (IMI)